PropThink

Biotech insights. Not investment or medical advice.
Disclaimer:

[PropThink @PropThinker]

$SLDB doing a financing at ~0EV isn't helping bio get over this hump.

$XBI investors get hosed even when early data seems promising

[PropThink @PropThinker]

Patients using GLP-1 globally across T2D/obesity has grown from approx. 7M in 2021 to nearly 20M by November 2024.

$NVO is global market share leader with 63%. $LLY 34%. Figures include older versions lira/dula/exen, as well as newer sema/tirz.

$VKTX $AMGN $PFE $MTSR $AZN

[PropThink @PropThinker]

LEK Consulting makes case that anti-obesity landscape moves into fragmented pathway, with distinct lines of therapy tailored to specific patient groups.

https://t.co/nG7cU1l0yv

Relevant example: $VERU in sarcopenic obesity

[PropThink @PropThinker]

$SRRK $BHVN $VERU $KROS $REGN $LLY

[Biotech Jim @JamesEKrause]

GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials

[PropThink @PropThinker]

Overlooking $NVO botched ambitious expectations for CagriSema, weight loss results look similar to $LLY tirzepatide.

GI tolerability/disc. rates still unknown. Novo has scope for improvement with titration. Seem to have competitive drug that is > sema alone.

Source: Cantor

[PropThink @PropThinker]

$IRWD ahead of $ZEAL in SBS after news of today's CRL and more trials needed. IRWD NDA Q1-25.

Apraglutide (1x/week) less efficacious than glepaglutide (2x/week). However, apraglutide sample size is much larger at n=110. Neither seems likely to take share from $TAK Gattex.

[PropThink @PropThinker]

@nomlastew Pre-funded warrants. Different from the traditional warrants that are dilutive.

Funds commonly use pre-funded warrants to stay below ownership limits (4.99% or 9.99%) and not be "affiliates".

[PropThink @PropThinker]

Avidity, Soleus and Perceptive Advisors already in the name. $MSCL $MSCLF $MSCL.TO

Stock has doubled so far in Q4. Money needed for planned Phase 2 in DMD.

https://t.co/voLXK7OFCd

[PropThink @PropThinker]

RTW Bio investor day 2024 talk highlights obesity, including RTW's newco Kailera (private), $LLY $NVO $VKTX $GPCR $ZEAL and many more.

https://t.co/0X173m8ys5

[PropThink @PropThinker]

Catch replay/transcript of DMD KOL call. Topics discussed:

-challenges faced by gene therapy & exon skippers $SRPT $PTCT $WVE
-how $MSCL $MSCLF is shifting treatment focus beyond dystrophin replacement
-fit for unconventional approaches $CAPR $EWTX

https://t.co/wWjmyB21OV

[PropThink @PropThinker]

Free DMD KOL call: Wed, Dec 4 @ 2PM ET

Topics:
-need for new approaches with functional benefits
-navigating therapeutic landscape $SRPT $EWTX $WAVE $CAPR $SLDB
-Why $MSCL.TO $MSCLF small molecule focused on muscle regeneration unlocks new understanding

https://t.co/6jqhBZMaVQ

[PropThink @PropThinker]

Free DMD KOL call in an hour @ 2PM ET discussing FDA’s stance on conventional oligo/gene therapy for DMD $SRPT $WAVE $SLDB and novel approaches from $EWTX $CAPR $MSCL.TO $MSCLF

Register here to attend: https://t.co/6jqhBZMaVQ

[PropThink @PropThinker]

Free DMD KOL call: Wed, Dec 4 @ 2PM ET

Topics:
-need for new approaches with functional benefits
-navigating therapeutic landscape $SRPT $EWTX $WAVE $CAPR $SLDB
-Why $MSCL.TO $MSCLF small molecule focused on muscle regeneration unlocks new understanding

https://t.co/6jqhBZMaVQ

[PropThink @PropThinker]

👀👀 $MSCL $MSCLF 6 different sell-side investor conferences (Oppenheimer, Jeffries, Stifel, Guggenheim, Cantor Fitzgerald, HCW) in the last three months.

[Satellos Bioscience @SatellosBio]

Satellos will participate in @Oppenheimer Movers in Rare Disease Summit on December 12, 2024 in New York City. Our CEO, @frank_satellos, will participate in a fireside chat at 9:50 am ET titled, “Polypharmacy in DMD and Neuromuscular Disease.”

Read the release here: https://t.co/V7GgjXS8um

$MSCL.to $MSCLF #raredisease #rarediseases #smallmolecule #regenmed #regenerativemedicine #Duchenne #musculardystrophy #DMD #Biotech

[PropThink @PropThinker]

Wednesday, December 4th, 2024 @ 2PM ET we will host a DMD KOL call to talk about the landscape in Duchenne, what others are doing $WVE $EWTX $CAPR, and get thoughts on $SRPT, exon-skipping, gene therapy and the role Muscle Stem Cells may play in the pathology of DMD. $MSCL $MSCLF

[Satellos Bioscience @SatellosBio]

Satellos is pleased to participate in a Duchenne KOL Investor Webinar on December 4, 2024. Don’t miss this deep dive into our novel small molecule therapeutic approach in development for the treatment of Duchenne muscular dystrophy.

🔗 Read more and register here: https://t.co/F4kPP7TWmd

$MSCL.to $MSCLF #raredisease #rarediseases #smallmolecule #regenmed #regenerativemedicine #Duchenne #musculardystrophy #DMD #Biotech

[PropThink @PropThinker]

Free DMD KOL call: Wed, Dec 4 @ 2PM ET

Topics:
-need for new approaches with functional benefits
-navigating therapeutic landscape $SRPT $EWTX $WAVE $CAPR $SLDB
-Why $MSCL.TO $MSCLF small molecule focused on muscle regeneration unlocks new understanding

https://t.co/6jqhBZMaVQ

[PropThink @PropThinker]

$BMY $MRK created decade long franchises with their PD-1 drugs. $LLY $NVO are forming similar patterns with GLP-1s.

Read what it means for fast followers and those who are hopeful with combinations $VKTX $PFE $AMGN $CRBP $BHVN $SRRK $BIOA $GPCR $KROS

https://t.co/kDqgmVWnYk

[PropThink @PropThinker]

@JamesEKrause $NVO acquired Embark for their NK2R agonist

https://t.co/ukwcBe21VN

[PropThink @PropThinker]

$NVO $LLY $VKTX

[Nature Reviews Drug Discovery @NatRevDrugDisc]

A fatty acid acylation strategy to extend the half-life of GLP-1 was critical in the development of the blockbuster semaglutide, highlights Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk in this interview https://t.co/W0d2c8Uab2

[PropThink @PropThinker]

$DCTH

the good: ramping Hezpato revenues, receives $25M for growth and expanding indications.

the bad: $25M triggered at $6/share when market price >$10.

[PropThink @PropThinker]

Highlighting another @encodelp note after the $DRUG $LBPH call

$GANX – Phase 1 PK/PD data two weeks ago. Increase in GCase activity, target engagement & CNS exposure in GBA1 related Parkinson’s Disease.

$VYGR $NBIX $1.5B deal
$MRK acquired Caraway $600M

https://t.co/sz8tJCTZHy

[PropThink @PropThinker]

Props to @encodelp for $DRUG

[Encode Ideas @encodelp]

Bright Minds lists on Nasdaq $DRUG. Early-stage selective 5HT2 co, with 2C program for dravet & 2A program for MDD/TRD. 2C program entering clinic imminently, 2A later next year. A recent interview with their founder can be found here. $ZGNX $CMPS https://t.co/MSqxep31Vt